Drugs / Ifenprodil
Ifenprodil
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06330077 | Mar 2024 → Mar 2027 expected | relapsing-remitting multiple sclerosis | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04318704 | Jul 2020 → May 2022 | idiopathic pulmonary fibrosis | Algernon Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04382924 | Aug → Dec 2020 | COVID-19 | Algernon Pharmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01896388 Comparator | Jan 2014 → Mar 2019 | post-traumatic stress disorder | Chiba University | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ifenprodil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04318704 ↗ |
| Known as | Ifenprodil hemitartrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL305187 ↗ |
| Known as | Ifenprodil Tartrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01896388 ↗ |
| Known as | NP-120 | “NP-120 (Ifenprodil) has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of Idiopathic Pulmonary Fibrosis (IPF).” NCT04318704 ↗1“NP-120 (Ifenprodil) is an N-methyl-D-Aspartate (NDMA) inhibitor that is specific for the NR2B subunit of the NMDA Receptor.” NCT04382924 ↗ |
| Known as | RC 61-91 | ChEMBL registry synonym — accepted as the source's own label CHEMBL305187 ↗ |
| Action | Inhibit | “the NMDA receptor antagonist ifenprodil tartrate may be a potential therapeutic drug for PTSD” NCT01896388 ↗ |
| Modality | Small molecule | — CHEMBL305187 ↗ |
| Route | Oral | “Oral Administration of Ifenprodil Tartrate 40mg/day” NCT01896388 ↗ |